Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
The purpose of this study is to determine if natalizumab in combination with Glatiramer
 Acetate (GA) is safe and effective in delaying progression of individuals diagnosed with
 relapsing-remitting Multiple Sclerosis (MS).
Inclusion Criteria:

 -  Diagnosis of MS as defined by McDonald et al., criteria # 1-4

 -  Between the ages of 18 and 55, inclusive

 -  Baseline EDSS score between 0.0 and 5.0, inclusive

 -  Have been treated with GA for at least the 12 months prior to randomization

 Exclusion Criteria:

 -  Primary progressive, secondary progressive or progressive relapsing MS

 -  MS relapse has occurred within the 50 days prior to randomization

 -  A clinically significant infectious illness

 -  History of, or abnormal lab result indicative of significant disease that would
 preclude the administration of a recombinant humanized antibody immunomodulating agent
 or GA for 20 weeks.